Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/20/2018 |
| Start Date: | October 28, 2016 |
| End Date: | December 2026 |
| Contact: | Andrew Talal, MD |
| Email: | ahtalal@buffalo.edu |
| Phone: | 716 829-6208 |
The primary goal of this study is to establish a database of people with varying levels of
hepatic fibrosis and various etiologies of liver disease for use in future research
protocols.
hepatic fibrosis and various etiologies of liver disease for use in future research
protocols.
The Fibroscan device will determine liver stiffness as well as the amount of fat through
another application on the machine called controlled attenuation parameter or Controlled
Attenuation Parameters (CAP). The liver stiffness measurements are then translated into a
score that tells how much liver fibrosis or fat is present. Patients identified with
potential for fatty liver or specific liver-related diseases causing fibrosis would be
approached for a voluntary FibroScan measurement. From these patients, the investigators will
collect information related to demographics, disease history, medical comorbidities, social
history, laboratory and radiologic parameters. This information, along with clinical data
associated with the patient will be placed in a database for use in identifying potential
subjects for future trials.
another application on the machine called controlled attenuation parameter or Controlled
Attenuation Parameters (CAP). The liver stiffness measurements are then translated into a
score that tells how much liver fibrosis or fat is present. Patients identified with
potential for fatty liver or specific liver-related diseases causing fibrosis would be
approached for a voluntary FibroScan measurement. From these patients, the investigators will
collect information related to demographics, disease history, medical comorbidities, social
history, laboratory and radiologic parameters. This information, along with clinical data
associated with the patient will be placed in a database for use in identifying potential
subjects for future trials.
Inclusion Criteria:
- Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis
- Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH)
but who do not have current steatosis (fat) or fibrosis scoring
- Subjects who have other known liver diseases ie: HCV
Exclusion Criteria:
- Patients less than 18 years of age
- Pregnancy
- Patients that do not want to be contacted for consideration in future research
studies.
- Patients diagnosed with ascites or peritoneal dialysis
- Body mass index (BMI) ≥40
We found this trial at
1
site
Buffalo, New York
Principal Investigator: Andrew H Talal, MD
Phone: 716-829-6208
Click here to add this to my saved trials
